NASDAQ · Biotechnology

Agenus Inc. (AGEN) Stock

$6.06 +1.34% NASDAQ: AGEN Healthcare

Agenus Inc. is a clinical-stage biotechnology firm operating globally, dedicated to the discovery and development of immuno-oncology therapies.

Valuation

MetricValue
Price$6.06
Market Cap$252.35M
P/E Ratio3.46
P/B Ratio-1.03
P/S Ratio2.01
EPS (TTM)$0.00
52-Week High$8.70
52-Week Low$2.71
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-23.05%
ROA34.65%
ROCE-13.05%
Gross Margin-18.42%
Operating Margin-18.42%
Net Margin52.16%
Debt/Equity-1.38
Current Ratio0.41

Annual Financials (USD)

Metric20212022202320242025
Revenue$296.0M$98.0M$156.0M$103.0M$114.0M
Operating Profit$26.0M$-179.0M$-160.0M$-120.0M$-21.0M
Net Profit$-24.0M$-220.0M$-246.0M$-227.0M$0
EPS$-2.11$-15.64$-13.75$-10.59$0.00
Op Margin8.7%-183.0%-102.1%-116.4%-18.0%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$466.0M$414.0M$314.0M$226.0M$227.0M
Total Liabilities$418.0M$468.0M$462.0M$533.0M$505.0M
Cash$292.0M$179.0M$76.0M$40.0M$3.0M
Borrowings$58.0M$78.0M$93.0M$95.0M$335.0M

Latest News

AGEN Stock Jumps on Securing $340M Financing to Fund Strategic Pivot Zacks · Jul 14, 2026 Agenus stock doubles as biotech narrows Phase 3 bet TheStreet · Jul 14, 2026 Agenus (AGEN) Moves 82.7% Higher: Will This Strength Last? Zacks · Jul 14, 2026 Agenus (AGEN) Is Up 74.9% After Durable Botensilimab Combo Data In Refractory Colorectal Cancer - Has The Bull Case Changed? Simply Wall St. · Jul 14, 2026 AGEN Stock Eyes Best Day Ever Following Strategic Shift To Earlier Colon Cancer Treatment Stocktwits · Jul 13, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$10.0M$-175.0M$-224.0M$-158.0M$-158.0M
Investing Cash Flow$-77.0M$-87.0M$-7.0M$-1.0M$-1.0M
Financing Cash Flow$6.0M$-3.0M$-4.0M$74.0M$84.0M
Net Cash Flow$192.0M$-113.0M$-102.0M$-36.0M$-36.0M
Free Cash Flow$-24.0M$-228.0M$-234.0M$-159.0M$-159.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.03
EV / EBITDA4.13
FCF Yield-63.01%
Quick Ratio0.41
Interest Coverage-0.38
Return 1Y1.98%
Return 3Y-80.16%
Return 5Y-95.26%

Ownership

Insiders Held6.72%
Institutions Held23.70%
Institutions Float Held25.41%
Institutional HolderSharesReport Date
Vanguard Capital Management LLC1,440,2322026-03-31
Vanguard Portfolio Management LLC1,195,1092026-03-31
Siren, L.L.C.1,064,2502026-03-31
Marshall Wace LLP688,2032026-03-31
Blackrock Inc.545,6622026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ABOS $2.27 -0.66% -1.17 $163.60M 0.00%
FATE $2.31 -0.43% -1.62 $269.25M 0.00%
HURA $2.09 -2.34% -3.75 $133.10M 0.00%
INO $1.04 +0.97% -2.73 $55.73M 0.00%
IRDOpus Genetics, Inc. $3.32 +7.63% -2.35 $273.71M 0.00%

About Agenus Inc.

Agenus Inc. is a clinical-stage biotechnology firm operating globally, dedicated to the discovery and development of immuno-oncology therapies. The company's innovative technological arsenal includes Retrocyte Display, a sophisticated antibody expression platform designed to identify fully human and humanized monoclonal antibodies, alongside other proprietary display technologies. Agenus is also actively involved in vaccine development programs, featuring the Prophage vaccine candidate and QS-21 Stimulon, a widely recognized saponin-based vaccine adjuvant. Its robust and diverse pipeline of therapeutic candidates targets various immune checkpoints and cancer pathways. Notable assets in clinical development include: Balstilimab: An anti-PD-1 antagonist that has successfully completed Phase II trials for the treatment of second-line cervical cancer. AGEN1181: A monospecific anti-CTLA-4 antibody currently undergoing Phase 1/2 clinical evaluation. AGEN2373: An anti-CD137 monospecific antibody in Phase 1 clinical trials. AGEN1423: A bi-functional anti-CD73/TGFß TRAP antibody, engineered to modulate the tumor microenvironment, which has concluded Phase 1 studies. AGEN1777: An anti-TIGIT bispecific antibody. AGEN1327: A human monoclonal antibody. INCAGN1876: An anti-GITR monospecific antibody. INCAGN1949: An anti-OX40 monospecific antibody. INCAGN2390: An anti-TIM-3 monospecific antibody. INCAGN2385: An anti-LAG-3 monospecific antibody. MK-4830: A monospecific antibody engineered to target ILT4. AGENT 797: An iNKT cell therapy, currently in Phase 1 for solid tumors, multiple myeloma, and viral ARDS, with ongoing clinical investigation for hematological malignancies and multiple myeloma/B cell indications. AGEN1884: A first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. utilizes a portfolio of trademarks, including ASV, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon, alongside its own company name. Strategic alliances are maintained with partners such as Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. Established in 1994, the company originally operated as Antigenics Inc. before rebranding to Agenus Inc. in January 2011. Its corporate headquarters are situated in Lexington, Massachusetts.

Agenus Inc. is led by CEO Garo H. Armen, employs 316 people, headquartered in US, publicly traded since 2000.

Agenus Inc. (AGEN) stock trades at $6.06 with a market capitalization of $252.35M. The stock is valued at a price-to-earnings (P/E) ratio of 3.46, price-to-book of -1.03, price-to-sales of 2.01. Over the past 52 weeks the stock has ranged between $2.71 and $8.70, and currently trades 30.3% below its 52-week high.

On profitability, Agenus Inc. generates a return on equity (ROE) of -23.05%, return on capital employed of -13.05%, an operating margin of -18.42%, a net profit margin of 52.16%.

Official website: www.agenusbio.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides